Group 1 - The core viewpoint of the article highlights the transfer of shares in Mace Health from Merrill Lynch Far East Limited to China International Capital Hong Kong Securities, with a market value of HKD 88.21 million, representing 10.53% of the company [1] - Mace Health reported a mid-year performance for 2025, showing revenue of RMB 125 million, an increase of 13.2% year-on-year [1] - The net profit for Mace Health reached RMB 13.239 million, reflecting a significant year-on-year growth of 5238.3% [1] - The basic earnings per share were reported at 2.45 cents, with a proposed interim dividend of 1.1 Hong Kong cents per share [1] Group 2 - The increase in total revenue is attributed to the recovery in the pharmaceutical industry and the accelerated transformation of domestic pharmaceutical companies towards evidence-driven marketing models, which has boosted the demand for precise omnichannel marketing solutions [1]
梅斯健康(02415)股东将股票由Merrill Lynch Far East Limited转入中国国际金融香港证券 转仓市值8821.08万港元